Dianthus Therapeutics (DNTH) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Dianthus Therapeutics (DNTH) over the past year, gaining 434.2% versus a gain of 144.6%. Over five years, PRAX leads with a -7.4% price change compared with -21.2% for DNTH. Praxis Precision Medicines is the larger company by market cap ($7.36 billion vs $4.60 billion), about 1.6 times the size, while Dianthus Therapeutics is growing revenue faster (-67.3% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | PRAX |
|---|---|---|
| Share price | $82.33 | $263.58 |
| Market cap | $4.60B | $7.36B |
| 1-day change | -3.01% | -5.19% |
| YTD return | +105.97% | -5.67% |
| 1-year return | +144.61% | +434.24% |
| 5-year return | -21.17% | -7.37% |
| EPS (TTM) | $-4.24 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $0 |
| Revenue growth (YoY) | -67.35% | -100.00% |
| Net income (latest FY) | $-162.34M | $-303.27M |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $392.70 |
| 52-week low | $32.22 | $50.56 |
| Distance from 52-week high | -30.16% | -32.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +71.03% | +144.49% |
| Average volume | 821.22K | 403.18K |
| Shares outstanding | 55.93M | 27.92M |
| Employees | 92 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed DNTH by 289.6 percentage points over the past year.
- Dianthus Therapeutics grew revenue faster in its latest fiscal year (-67.35% vs -100.00%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
DNTH vs PRAX FAQ
Which is bigger, Dianthus Therapeutics or Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $7.36B compared with $4.60B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or PRAX?
PRAX returned +434.24% over the past 12 months, compared with +144.61% for DNTH (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.